Search results
Guillain-Barre syndrome 'more common than expected' with RSV vaccine in older people, CDC reiterates
WGRZ-TV Buffalo· 4 days agoGovernment officials still say the benefits of the shots outweigh the risks. Health officials have...
After key rare disease win, Annexon eyes $144 million raise - San Francisco Business Times
The Business Journals· 1 day agoThe Brisbane company (Nasdaq: ANNX) said Tuesday that its drug, called ANX-005, produced positive...
Guillain-Barre Syndrome Rates After RSV Shots in Sync With Trial Data, CDC Says
MedPage Today· 7 days agoReports of Guillain-Barré syndrome (GBS) following respiratory syncytial virus (RSV) vaccination in adults ages 60 and up were higher than expected, but ...
Annexon shares leap as Guillain-Barré drug reduces disability in phase 3
FierceBiotech· 2 days agoAnnexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune...
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Verywell Health via Yahoo News· 1 day agoImportantly, none of the participants experienced Guillain-Barré syndrome (GBS), a rare neurological...
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Zacks via Yahoo Finance· 1 day agoAnnexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of...
Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study
Benzinga via Yahoo Finance· 2 days agoOn Tuesday, Annexon Inc (NASDAQ:ANNX) released topline results from its Phase 3 trial in patients...
Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data
Market Watch· 3 days agoThe company said Monday it will discuss results for its ANX005 treatment for Guillain-Barré Syndrome, with a conference call and webcast slated for Tuesday ...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Annexon Shares Rise 29% After Positive Results From Phase 3 ANX005 Trial
Market Watch· 2 days agoAnnexon shares were up 29% at $5.90 in premarket trading after the company reported positive topline results from its Phase 3 trial for ANX005 in patients with Guillain-< ...